Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer.
Nuclear factor-kappaB (NF-kappaB), hypoxia-inducible factor 1alpha (HIF-1alpha), and vascular endothelial growth factor (VEGF) are involved in cell proliferation, invasion, angiogenesis, and metastases. The principal objective of this study was to assess the prognostic significance of NF-kappaB, HIF-1alpha, and VEGF expression in stage III colorectal cancer. Tumor tissues from 148 patients with stage III colorectal carcinoma, all of whom underwent potentially curative resection, were immunohistochemically evaluated using monoclonal antibodies against NF-kappaB, HIF-1alpha, and VEGF. Positivity rates of NF-kappaB, HIF-1alpha, and VEGF were 47.3%, 42.6%, and 61.5%, respectively. NF-kappaB expression in tumor tissues was correlated significantly with HIF-1alpha expression (P < 0.001), VEGF expression (P = 0.044), and the presence of vascular invasion (P = 0.013). Univariate analysis demonstrated that NF-kappaB expression was associated with poor 5-year overall survival (55.8 months vs 76.9 months, P = 0.012). Multivariate analysis verified that NF-kappaB was independently associated with adverse outcomes (relative risk: 1.92, P = 0.049). However, HIF-1alpha and VEGF did not appear to be related to clinical outcomes. NF-kappaB expression in tumor tissue is associated with angiogenesis and poor 5-year overall survival in stage III colorectal cancer patients.
Kwon
Hyuk-Chan
HC
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Kim
Sung Hyun
SH
Oh
Sung Yong
SY
Lee
Suee
S
Kwon
Kyung A
KA
Lee
Jong Hoon
JH
Choi
Hong-Jo
HJ
Park
Ki-Jae
KJ
Lee
Hyung-Sik
HS
Roh
Mee Sook
MS
Kim
Hyo-Jin
HJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000737:chemistry / Q000473:pathology*; D005260:Female; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000032:analysis / Q000502:physiology*; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016328:NF-kappa B / Q000032:analysis / Q000502:physiology*; D009367:Neoplasm Staging; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000502:physiology*
C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D016328:NF-kappa B; D042461:Vascular Endothelial Growth Factor A
J Korean Med Sci. 2007 Sep;22 Suppl:S5-S10
17923755
Clin Cancer Res. 2007 Oct 1;13(19):5670-4
17908955
Surg Oncol. 2007 Dec;16 Suppl 1:S25-7
18023174
J Clin Oncol. 2001 Feb 15;19(4):1207-25
11181687
Cancer Cell. 2004 Sep;6(3):203-8
15380510
Int J Colorectal Dis. 2007 Aug;22(8):863-8
17216219
Nat Med. 1999 Apr;5(4):412-7
10202930
Biochem J. 2008 Jun 15;412(3):477-84
18393939
Endocr Rev. 1997 Feb;18(1):4-25
9034784
J Cell Biochem. 2009 Aug 15;107(6):1053-62
19479945
J Clin Pathol. 2008 May;61(5):658-64
17908805
Mol Biol Cell. 2007 Dec;18(12):4691-7
17898080
Trends Biochem Sci. 1999 Feb;24(2):68-72
10098401
Clin Cancer Res. 2001 Jun;7(6):1661-8
11410504
Clin Cancer Res. 2009 Apr 1;15(7):2248-58
19276252
Cancer Res. 1999 Nov 15;59(22):5830-5
10582706
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
7539918
Clin Cancer Res. 2004 Dec 15;10(24):8554-60
15623639
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Mod Pathol. 2002 Dec;15(12):1374-80
12481020
Int J Cancer. 2003 Jun 10;105(2):176-81
12673675
J Clin Oncol. 2005 Aug 20;23(24):5635-43
16110022
J Surg Res. 2008 Jun 1;147(1):99-107
17655863
Int J Colorectal Dis. 2004 Jan;19(1):18-22
12827408
World J Gastroenterol. 2003 Jun;9(6):1227-30
12800229